For years, GLP-1 drugs like Wegovy and Zepbound have transformed the discussion around obesity — but left millions locked out by high price tags, including Medicare recipients. That changes this week.

Federal regulators have agreed to review a Swiss pharmaceutical company's applications for two cheaper generic versions of ...

Medicare will soon cover costs of weight-loss drugs. Here’s what you can expect to pay. - Popular Novo Nordisk and Eli Lilly ...

Zealthy announced today the launch of its enhanced virtual weight-loss care platform, designed to simplify access to provider-guided obesity treatment through integrated telehealth services, insurance ...

Novo Nordisk'sNVO oral Wegovy snagged 3,071 prescriptions in its first week on the market, an analyst said Friday. Novo Nordisk stock jumped on the news. In comparison, Eli Lilly'sLLY weight-loss shot ...

A class-action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly’s blockbuster GLP-1 drug to treat obesity. When the major pharmacy benefit manager ...

Meaghan is an editor and writer who also has experience practicing holistic medicine as an acupuncturist and herbalist. She's passionate about helping individuals live full, healthy and happy lives at ...

Sign up here to get The Boston Globe’s latest food stories delivered to your inbox once a week. In April, I went public with a secret: I’d begun taking the weight ...

On the heels of striking a deal with the Trump administration to reduce the prices of several of its most popular drugs for U.S. patients, Eli Lilly has unveiled additional savings for cash-paying ...

Researchers say that GLP-1 drugs containing tirzepatide (Zepbound, Mounjaro) may lead to greater weight loss. Image Credit: Tatsiana Volkava/Getty ImagesThis article originally appeared onHealthline A ...